Nkarta, Inc. NKTX
Set alert
As of Nov 3, 1:34 PM ET
- YTD
- -16.49%
- 1 year
- -25.36%
- Open
- 1.54
- Prev close
- 1.52
- Mkt cap
- 110.66M
- Vol
- 409.43K
- Avg vol
- 752.65K
- EPS
- -1.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.52
- High
- 1.60
- Forward P/E
- -1.42
- Beta
- 0.87
- Short ratio
- 5.44
- Inst. own
- 99.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 3.03
- 200-d avg
- 5.86
- 1y target
- 15.83
5D chart
Signals (54)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 10:10 AM | 1 day ago |
| SMA: Bearish | Nov 2, 10:00 AM | 1 day ago |
| SMA: Bullish | Oct 30, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 30, 1:45 PM | 4 days ago |
| RSI: Oversold | Oct 30, 12:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 30, 12:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 30, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 30, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 4 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 4 days ago |
Newest 20 of 54.
News
-
1 day ago benzinga.com
HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12
HC Wainwright & Co. analyst Douglas Tsao assumes Nkarta (NASDAQ:NKTX) with a Buy rating and announces Price Target of $12.
1 month ago defenseworld.net
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta (NASDAQ: NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including…
1 month ago marketbeat.com
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta NASDAQ: NKTX said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including…
1 month ago defenseworld.net
Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report)'s stock price fell 3.5% during trading on Friday. The stock traded as low as $2.73 and last traded at $2.75. 681,083 shares were traded during trading,…
1 month ago globenewswire.com
Nkarta to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to…
1 month ago globenewswire.com
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…
2 months ago defenseworld.net
6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.
BlackRock Inc. bought a new stake in Nkarta, Inc. (NASDAQ: NKTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,300,212…
-
2 months ago benzinga.com
Stifel Maintains Buy on Nkarta, Lowers Price Target to $10
Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $11 to $10.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $16 to $14.
-
2 months ago benzinga.com
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 74.19 percent decrease over losses of $(0.31)…
3 months ago globenewswire.com
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1…
4 months ago globenewswire.com
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.
5 months ago prnewswire.com
The $13 Million Company Teaching the Immune System to Hunt Cancer
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
-
5 months ago benzinga.com
Nkarta Q1 EPS $(0.37), Inline
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period…
5 months ago globenewswire.com
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based…
6 months ago zacks.com
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
6 months ago globenewswire.com
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…
6 months ago globenewswire.com
Nkarta to Participate in Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to…
7 months ago defenseworld.net
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Hold” by Analysts
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has…
-
7 months ago benzinga.com
Mizuho Maintains Outperform on Nkarta, Lowers Price Target to $12
Mizuho analyst Salim Syed maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price target from $14 to $12.
-
7 months ago benzinga.com
Nkarta Q4 EPS $(0.37) Misses $(0.34) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.34) by 9.79 percent. This is a 5.71 percent decrease over losses of $(0.35) per…
7 months ago globenewswire.com
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…
8 months ago defenseworld.net
Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review
Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two…
8 months ago globenewswire.com
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to…
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
10 months ago defenseworld.net
Nkarta, Inc. $NKTX Shares Sold by AWM Investment Company Inc.
AWM Investment Company Inc. trimmed its position in shares of Nkarta, Inc. (NASDAQ: NKTX) by 30.0% during the second quarter, according to the company in its most recent Form 13F filing with the…
11 months ago globenewswire.com
Nkarta to Participate in Evercore Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to…
11 months ago seekingalpha.com
Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason
Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune diseases, despite current market pessimism. NKX019, the lead CAR-NK candidate, shows promising early…
-
11 months ago benzinga.com
Stifel Maintains Buy on Nkarta, Lowers Price Target to $11
Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $12 to $11.
-
11 months ago benzinga.com
Nkarta Q3 EPS $(0.29) Beats $(0.35) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 16.43 percent. This is a 25.64 percent increase over losses of $(0.39) per…
-
1 year ago benzinga.com
Nkarta To Present NKX019 Data At ACR Convergence 2025 Showing Immune Reset In Non-Hodgkin Lymphoma And Preclinical Efficacy In Vitro Autoimmune Disease Models
Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
2 years ago benzinga.com
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
-
2 years ago benzinga.com
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
2 years ago benzinga.com
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode…
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
-
3 years ago benzinga.com
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 369 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 112 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 283 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 109 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 43 companies set new 52-week lows.
-
3 years ago benzinga.com
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 220 stocks hit new 52-week lows.